This study investigates the use of MEM-288 in patients with advanced solid tumors. MEM-288 is a conditionally replicative oncolytic adenovirus vector designed to selectively replicate in cancer cells, causing cell lysis and stimulating an anti-tumor immune response.
The study evaluates the safety, tolerability, and potential effectiveness of MEM-288 both as a standalone treatment and in combination with standard therapies. It looks at how MEM-288 might work with other treatments to improve immune responses against tumors.
- Who can participate: Adults aged 18 and older with advanced solid tumors, including NSCLC, cSCC, and other cancers, may participate. Participants must have progressed following specific previous therapies and have a tumor lesion accessible for injection.
- Study details: Participants will receive MEM-288 through injections directly into the tumor. Some may also receive standard care treatments like nivolumab or docetaxel, which are used to enhance immune system activity against cancer. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand